BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35004327)

  • 1. The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia.
    Sin CF; Man PM
    Front Oncol; 2021; 11():802832. PubMed ID: 35004327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe.
    Din RU; Jiao A; Qiu Y; Mohan AAM; Yuen KC; Wong HT; Wan TM; Wong PO; Sin CF
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
    Niewerth D; Kaspers GJ; Jansen G; van Meerloo J; Zweegman S; Jenkins G; Whitlock JA; Hunger SP; Lu X; Alonzo TA; van de Ven PM; Horton TM; Cloos J
    J Hematol Oncol; 2016 Sep; 9(1):82. PubMed ID: 27599459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New orally active proteasome inhibitors in multiple myeloma.
    Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabr├▓ L; Musolino C
    Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma.
    Jayaweera SPE; Wanigasinghe Kanakanamge SP; Rajalingam D; Silva GN
    Front Oncol; 2021; 11():740796. PubMed ID: 34858819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
    Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
    Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From bortezomib to other inhibitors of the proteasome and beyond.
    Buac D; Shen M; Schmitt S; Kona FR; Deshmukh R; Zhang Z; Neslund-Dudas C; Mitra B; Dou QP
    Curr Pharm Des; 2013; 19(22):4025-38. PubMed ID: 23181572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of bortezomib with chemotherapy to treat┬árelapsed/refractory acute lymphoblastic leukaemia of childhood.
    Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
    Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitors: structure and function.
    Nunes AT; Annunziata CM
    Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
    Kubiczkova L; Pour L; Sedlarikova L; Hajek R; Sevcikova S
    J Cell Mol Med; 2014 Jun; 18(6):947-61. PubMed ID: 24712303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitors.
    Teicher BA; Tomaszewski JE
    Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.
    Offidani M; Corvatta L; Caraffa P; Gentili S; Maracci L; Leoni P
    Onco Targets Ther; 2014; 7():1793-800. PubMed ID: 25302026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
    Niewerth D; Franke NE; Jansen G; Assaraf YG; van Meerloo J; Kirk CJ; Degenhardt J; Anderl J; Schimmer AD; Zweegman S; de Haas V; Horton TM; Kaspers GJ; Cloos J
    Haematologica; 2013 Dec; 98(12):1896-904. PubMed ID: 24056819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
    O'Connor OA
    Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of the safety profile of proteasome inhibitors for treating various cancers.
    Wang H; Guan F; Chen D; Dou QP; Yang H
    Expert Opin Drug Saf; 2014 Aug; 13(8):1043-54. PubMed ID: 25005844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
    Kuhn DJ; Orlowski RZ; Bjorklund CC
    Curr Cancer Drug Targets; 2011 Mar; 11(3):285-95. PubMed ID: 21247387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
    Nooka A; Gleason C; Casbourne D; Lonial S
    Biologics; 2013; 7():13-32. PubMed ID: 23386784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.